ZSP1273 200 mg

DRUG2 trials

Sponsors

Guangdong Zhongsheng Pharmaceutical Co., Ltd., Guangdong Raynovent Biotech Co., Ltd

Conditions

InfluenzaInfluenza A

Phase 1

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

CompletedNCT03679143

Guangdong Zhongsheng Pharmaceutical Co., Ltd.Influenza

Start: 2018-09-20End: 2019-04-26Updated: 2019-08-14

Phase 2

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

CompletedNCT04024137

Guangdong Raynovent Biotech Co., LtdInfluenza A

Start: 2019-12-07End: 2020-05-18Updated: 2020-06-04

Related Papers

Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

2024-02-0512 citations

Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects

Expert Opinion on Investigational Drugs2021-10-1717 citations